Clinical trial
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate…
NCT00089609 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00089609 |
|---|---|
| Title | Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer |
| Official title | A Phase II Trial of Docetaxel, Thalidomide, Prednisone and Bevacizumab in Patients With Androgen-Independent Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Biological, Drug, Genetic, Other |
| Interventions | Docetaxel, Thalidomide, Prednisone, bevacizumab, polymorphism analysis, immunoenzyme technique, laboratory biomarker analysis, pharmacological study |
| Enrollment | 73 |
| Start date | Apr 19, 2005 |
| Primary completion | Dec 31, 2011 |
| Completion | Jan 9, 2018 |
| First posted | Aug 9, 2004 |
| Last update posted | Apr 20, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: